Infectious diseases and their pandemics periodically attract public interests due to difficulty in treating the patients and the consequent high mortality. Sepsis caused by an imbalanced systemic inflammatory response to infection often leads to organ failure and death. The current therapeutic intervention mainly includes “the sepsis bundles,” antibiotics (antibacterial, antiviral, and antifungal), intravenous fluids for resuscitation, and surgery, which have significantly improved the clinical outcomes in past decades; however, the patients with fulminant sepsis are still in desperate need of alternative therapeutic approaches. One of the potential supportive therapies, extracorporeal blood treatment, has emerged and been developed for improving the current therapeutic efficacy. Here, I overview how the treatment of infectious diseases has been assisted with the extracorporeal adjuvant therapy and the potential utility of various nanobiotechnology and microfluidic approaches for developing new auxiliary therapeutic methods.

中文翻译：

---

用于治疗体外循环脓毒症的多尺度生物流体和纳米生物技术方法。

传染病及其流行病由于难以治疗患者和随之而来的高死亡率而定期引起公众关注。由对感染的不平衡全身炎症反应引起的败血症通常导致器官衰竭和死亡。目前的治疗干预主要包括“脓毒症束”、抗生素（抗菌、抗病毒和抗真菌）、用于复苏的静脉输液和手术，在过去几十年中显着改善了临床结果；然而，暴发性脓毒症患者仍迫切需要替代治疗方法。一种潜在的支持疗法，即体外血液治疗，已经出现并被开发用于提高当前的治疗效果。这里，